# Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma

> **NCT07207278** · — · RECRUITING · sponsor: **First People's Hospital of Hangzhou** · enrollment: 39 (estimated)

## Conditions studied

- Signet Ring Cell Carcinoma of the Lung

## Interventions

- **DRUG:** Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line

## Key facts

- **NCT ID:** NCT07207278
- **Lead sponsor:** First People's Hospital of Hangzhou
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-10-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07207278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07207278, "Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07207278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*